Exscientia Plc (EXAI) has released an update.
Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, with the transaction aimed at combining their complementary portfolios and technology platforms to accelerate drug discovery and development. Exscientia shareholders are urged to vote on the proposed scheme of arrangement, which will involve exchanging each Exscientia share for 0.7729 shares of Recursion Class A Common Stock. The success of the acquisition hinges on the approval of both Recursion stockholders and Exscientia shareholders, with a special meeting scheduled for November 12, 2024.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
